June 26, 2023
Life value
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
THROUGH THE MPP ORGANIZATION, STELLAPHARM GETS THE 3rd APPROVAL TO PRODUCE SHIONOGI’S COVID-19 ORAL PILL
As one of seven generic drug manufacturers selected by MPP and becoming a sub-licensee of Shionogi – a Japanese pharmaceutical manufacturer to produce of XOCOVA™ drug, generic version. Stellapharm is honored and proud to have contributed to repelling the COVID-19 pandemic with drugs. This is the third oral product in the world to be recognized and included in the treatment regimen for SARS-CoV-2, including: Molnupiravir – LAGEVRIOTM by MSD, Nirmatrelvir – PAXLOVIDTM by Pfizer and Ensitrelvir – XOCOVATM by Shionogi.
You May like
18
Mar 2022
THROUGH THE MPP ORGANIZATION, STELLAPHARM GETS THE APPROVAL TO PRODUCE PFIZER’S ANTI-COVID-19 PILL
On February 21, 2022, Stellapharm officially signed a contract with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce a generic version of Pfizer’s oral COVID-19 treatment, nirmatrelvir, which will be co-packaged with ritonavir, under the voluntary licensing agreement between Pfizer and the MPP.
20
Jan 2022
THROUGH THE MPP ORGANIZATION, STELLAPHARM GETS THE APPROVAL FROM MSD TO PRODUCE MOLNUPIRAVIR IN VIETNAM
On January 10, 2022, Stellapharm officially signed an agreement with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce the COVID-19 treatment molnupiravir under the “Voluntary Licensing” program for MSD, a trade name of Merck & Co., Inc., Kenilworth, NJ, USA.